GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Accelerate Diagnostics
Accelerate Diagnostics produces systems for rapid bacterial identification and antibiotic susceptibility testing. Its stock price reflects the slow adoption of its technology in hospitals, despite the critical importance of combating antibiotic resistance.
Share prices of companies in the market segment - Medanalysis
Accelerate Diagnostics provides systems for rapid bacterial identification and antibiotic susceptibility testing, helping combat sepsis. We've categorized it as a "Medanalysis" company. The chart below shows how the market rates technologies for combating antibiotic resistance.
Broad Market Index - GURU.Markets
Accelerate Diagnostics is a diagnostics company developing platforms for rapid pathogen identification and antibiotic susceptibility testing. As part of the GURU.Markets index, it combats the problem of superbugs. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
AXDX - Daily change in the company's share price Accelerate Diagnostics
For Accelerate Diagnostics, Inc., a company specializing in rapid infection diagnostics, daily volatility reflects the sensitivity of its systems to sales. This metric is an indicator of demand for innovative microbiology solutions.
Daily change in the price of a set of shares in a market segment - Medanalysis
Accelerate Diagnostics provides platforms for rapid pathogen identification and antibiotic susceptibility testing. The medical diagnostics sector is competitive and crucial for fighting infections. The chart below shows the volatility in this niche, helping to assess the AXDX trend.
Daily change in the price of a broad market stock, index - GURU.Markets
Accelerate Diagnostics produces systems for rapid infection diagnostics and antibiotic susceptibility testing. This medtech company's stock reflects the growing problem of antibiotic resistance. Its price movement reflects the contribution of innovative medicine to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Accelerate Diagnostics
For Accelerate Diagnostics, year-over-year performance is a story of its struggle to implement its rapid sepsis diagnostic platform. Its market cap change over the past 12 months reflects its success (or failure) in deploying its Pheno® system in hospital labs. Its valuation is a bet on its technology's potential to speed up antibiotic selection.
Annual dynamics of market capitalization of the market segment - Medanalysis
Accelerate Diagnostics, Inc. is a diagnostics company developing rapid antibiotic susceptibility testing systems. This chart shows how its innovative technology, the struggle for widespread adoption in hospitals, and competition are impacting its performance in the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Accelerate Diagnostics, a company that creates systems for rapid bacterial identification and antibiotic susceptibility testing, is tackling the problem of antibiotic resistance. Its annual market capitalization growth demonstrates how quickly hospitals are ready to implement its life-saving technology.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Accelerate Diagnostics
Accelerate Diagnostics is a molecular diagnostics company specializing in sepsis testing. Its monthly performance reflects the pace of its platform adoption in hospital laboratories. Quarterly sales reports for systems and consumables are key.
Monthly dynamics of market capitalization of the market segment - Medanalysis
Accelerate Diagnostics develops systems for rapid bacterial identification and antibiotic susceptibility testing. This is critical to combating sepsis and resistance. The chart below shows how investors assessed the prospects of companies whose technologies could save lives and revolutionize infection treatment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Accelerate Diagnostics creates systems for the rapid identification of bacterial infections. Its technology can save lives by helping doctors prescribe the right antibiotics faster. Its stock price depends on the speed of its systems' installation in hospitals, not on general market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Accelerate Diagnostics
Accelerate Diagnostics, a company specializing in rapid infection diagnostics, is news-sensitive. Its weekly price action depends on the pace of hospital adoption of its system and news about the fight against antibiotic resistance. The chart below shows how short-term developments in the healthcare sector affect the company's valuation.
Weekly dynamics of market capitalization of the market segment - Medanalysis
Accelerate Diagnostics creates systems for rapid bacterial identification and antibiotic susceptibility testing. This is critical in the fight against superbugs. The chart below shows how the company's stock outperforms the medical diagnostics sector based on expectations for this technology.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Accelerate Diagnostics is a medical technology company. This chart compares its weekly performance to the broader market. It helps understand whether the company is moving in tandem with the medical technology sector or whether its shares are more sensitive to news about its product rollouts and regulatory decisions.
Market capitalization of the company, segment and market as a whole
AXDX - Market capitalization of the company Accelerate Diagnostics
The valuation of Accelerate Diagnostics, Inc. on the chart reflects its struggle to adopt its platform for rapid bacterial identification and antibiotic susceptibility testing. The company's market cap demonstrates how difficult it is to convince conservative hospital labs to adopt new technology, even if it can save lives.
AXDX - Share of the company's market capitalization Accelerate Diagnostics within the market segment - Medanalysis
Accelerate Diagnostics' market share in the medical testing sector reflects its focus on rapid sepsis diagnosis. Its market share is based on its system, which can significantly reduce the time it takes to determine bacterial susceptibility to antibiotics, a critical step in saving patients' lives.
Market capitalization of the market segment - Medanalysis
The chart below is a barometer of the rapid infectious disease diagnostics market. Accelerate Diagnostics is one of the players in this field. The dynamics in the chart reflect how the market values technologies that can accelerate antibiotic susceptibility testing.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's the market value of the revolution in the fight against sepsis. Accelerate Diagnostics' market cap is the valuation of its system, which quickly identifies bacteria and selects antibiotics. The line shows how this life-saving technology is competing for its share of the global healthcare economy.
Book value capitalization of the company, segment and market as a whole
AXDX - Book value capitalization of the company Accelerate Diagnostics
This chart illustrates Accelerate Diagnostics' technological foundation. Its assets include patents and the Pheno® system for rapid bacterial identification and antibiotic susceptibility testing. The chart's progress shows how the company is investing in its sepsis platform.
AXDX - Share of the company's book capitalization Accelerate Diagnostics within the market segment - Medanalysis
Accelerate Diagnostics' core assets are its production lines for rapid sepsis and antibiotic resistance diagnostic systems. The chart shows the company's share of this critical hospital production infrastructure.
Market segment balance sheet capitalization - Medanalysis
Against the backdrop of the capital-intensive pharmaceutical industry, Accelerate Diagnostics has chosen the diagnostics industry. Its business requires a unique resource base—production lines for its rapid testing systems. The chart illustrates the scale of the industry in which the company occupies its high-tech niche.
Book value of all companies included in the broad market index - GURU.Markets
Accelerate Diagnostics creates systems for rapid bacterial identification and antibiotic susceptibility testing. The company's assets include factories that manufacture these "rapid labs" for hospitals. The graph shows the material impact of this technology in the fight against superbugs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Accelerate Diagnostics
Accelerate Diagnostics develops systems for rapid bacterial identification and antibiotic susceptibility testing. Its value lies in its life-saving technology. The chart below shows how the market perceives the speed of hospital adoption of its systems and its potential to transform approaches to treating infections.
Market to book capitalization ratio in a market segment - Medanalysis
Accelerate Diagnostics, Inc. develops systems for rapid bacterial identification and antibiotic susceptibility testing. Its value lies in this life-saving technology. This chart shows how the market perceives its potential in the fight against antibiotic resistance.
Market to book capitalization ratio for the market as a whole
Accelerate Diagnostics develops systems for rapid bacterial identification and antibiotic susceptibility testing. This chart shows how the market is assessing their technology in the fight against the growing problem of antibiotic resistance. The trend reflects the adoption of their systems in hospitals.
Debts of the company, segment and market as a whole
AXDX - Company debts Accelerate Diagnostics
Accelerate Diagnostics, a company developing systems for rapid bacterial identification and antibiotic susceptibility testing, is leveraging its financial structure to commercialize its platform. This chart shows how the company is investing in sales and marketing to convince hospitals to adopt its expensive but potentially life-saving equipment.
Market segment debts - Medanalysis
Accelerate Diagnostics is developing a platform for rapid bacterial identification and antibiotic susceptibility testing. This chart illustrates how its leverage reflects the complex and slow process of implementing this innovative technology in hospitals, requiring significant investment in sales and marketing.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Accelerate Diagnostics
Axonics is a fast-growing medical technology company producing implantable devices for the treatment of bladder and bowel dysfunction. This chart shows how the company is using capital to fund its aggressive growth, including expanding its sales and R&D departments.
Market segment debt to market segment book capitalization - Medanalysis
Accelerate Diagnostics provides rapid identification and antibiotic susceptibility testing solutions for patients with severe infections. This chart compares its debt to the overall market capitalization of the entire sector. It shows how the company finances its innovative diagnostic platforms.
Debt to book value of all companies in the market
Accelerate Diagnostics provides systems for rapid bacterial identification and antibiotic susceptibility testing, which is critical in the fight against sepsis. This graph of total market debt helps understand the financial environment in which the company is raising capital to install its systems in hospitals, a lengthy and costly process.
P/E of the company, segment and market as a whole
P/E - Accelerate Diagnostics
This metric for Accelerate Diagnostics, a medical diagnostics company, reflects the challenges of commercialization. The P/E ratio (if positive) reflects how investors assess its ability to convince hospitals to implement its rapid antibiotic susceptibility testing system.
P/E of the market segment - Medanalysis
Accelerate Diagnostics develops and markets systems for rapid bacterial identification and antibiotic susceptibility testing. Their technology allows doctors to prescribe the right treatment hours or even days earlier. This chart shows the average rating for the medical testing sector, reflecting the market's appreciation for technologies that help combat antibiotic resistance.
P/E of the market as a whole
Accelerate Diagnostics is developing a platform for rapid microbial identification and antibiotic susceptibility testing. The company's technology aims to combat the rise of antibiotic resistance. This sentiment chart helps understand how investors value companies solving critical healthcare problems.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Accelerate Diagnostics
Accelerate Diagnostics is developing a platform for rapid bacterial identification and antibiotic susceptibility testing. This chart shows expected future revenue, which depends on the implementation of its system in hospitals to combat sepsis and antibiotic resistance.
%20P%2FE%20Accelerate%20Diagnostics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Accelerate-Diagnostics&v=1772513437964 "Chart of the company's future (projected) P/E Accelerate Diagnostics")
Future (projected) P/E of the market segment - Medanalysis
Accelerate Diagnostics provides a platform for rapid bacterial identification and antibiotic susceptibility testing, which is critical in the fight against sepsis. This chart reflects how the market perceives the adoption of its technology in hospitals, comparing Accelerate to other diagnostic companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772513437980 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
Accelerate Diagnostics develops platforms for rapid diagnostics of infectious diseases and antibiotic susceptibility testing. Demand for their systems is driven by hospitals' efforts to combat sepsis and antibiotic resistance. This trend, reflecting general sentiment, influences hospitals' willingness to invest in advanced diagnostic equipment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513437989 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Accelerate Diagnostics
Accelerate Diagnostics develops and markets systems for rapid pathogen identification and antibiotic susceptibility testing. Its revenue depends on sales of instruments and consumables to laboratories. This chart shows how demand for solutions to combat antibiotic resistance impacts the company's financial performance.
Profit of companies in the market segment - Medanalysis
Accelerate Diagnostics provides solutions for the rapid diagnosis of infections that cause sepsis. This graph, showing overall sector revenue, reflects the fight against antimicrobial resistance. The Accelerate platform's ability to rapidly identify pathogens and their susceptibility to antibiotics has the potential to save lives and have a profound impact on the entire industry.
Overall market profit
Accelerate Diagnostics provides platforms for rapid bacterial identification and antibiotic susceptibility testing. In an era of growing antibiotic resistance, its technology has the potential to save lives and reduce hospital stays.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Accelerate Diagnostics
Accelerate Diagnostics provides systems for rapid pathogen identification and antibiotic susceptibility testing. Future revenue projections depend on the adoption of their diagnostic platforms in hospital laboratories.
%20profit%20of%20the%20company%20Accelerate%20Diagnostics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Accelerate-Diagnostics&v=1772513438021 "Graph of future (projected) profit of the company Accelerate Diagnostics")
Future (predicted) profit of companies in the market segment - Medanalysis
Accelerate Diagnostics provides systems for rapid identification of microorganisms and determination of their susceptibility to antibiotics. This chart reflects revenue expectations for the entire medical analytics sector. It helps assess how the company's technology, which combats antibiotic resistance, compares to overall diagnostic trends.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772513438023 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
Accelerate Diagnostics provides platforms for rapid infection diagnostics and antibiotic susceptibility testing. This is critical to the fight against sepsis. This schedule is important because the implementation of expensive diagnostic systems depends on hospital capital budgets. During periods of economic growth, hospitals invest more actively in laboratory modernization.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513438033 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Accelerate Diagnostics
Accelerate Diagnostics develops diagnostic platforms for the rapid detection of bacterial infections and their antibiotic resistance. This chart, plotting market capitalization against revenue, reflects its struggle to gain hospital adoption. It shows how investors view its life-saving technology and its slow progress toward commercialization.
P/S market segment - Medanalysis
Accelerate Diagnostics develops platforms for rapid microbial identification and antibiotic susceptibility testing. The company's technology helps combat sepsis and antibiotic resistance. This chart reflects the market's willingness to pay for revenue in the medical diagnostics sector, demonstrating confidence in Accelerate Diagnostics' ability to save lives.
P/S of the market as a whole
Accelerate Diagnostics provides solutions for rapid diagnosis of infections that cause sepsis, allowing doctors to prescribe the right antibiotics faster. This chart shows how investors value companies in the critical field of diagnostics, where speed saves lives.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Accelerate Diagnostics
Accelerate Diagnostics provides solutions for rapid infection diagnostics and antibiotic susceptibility testing. This chart shows how investors value the company based on its projected future sales. It reflects their belief that its technology will help combat antibiotic resistance.
%20P%2FS%20Accelerate%20Diagnostics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Accelerate-Diagnostics&v=1772513438088 "The graph of the company's future (projected) P/S Accelerate Diagnostics")
Future (projected) P/S of the market segment - Medanalysis
Accelerate Diagnostics develops platforms for rapid infectious disease diagnostics and antibiotic susceptibility testing. The chart shows the average estimated future revenue for the medical diagnostics sector. It helps understand how the market perceives the company's technology's ability to combat antibiotic resistance and its commercial prospects.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772513438095 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
Accelerate Diagnostics (AXDX) develops platforms for rapid infectious disease diagnostics and antibiotic susceptibility testing. Demand for their technology is driven by the global problem of antibiotic resistance. This graph does not reflect their potential to save lives and optimize treatment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513438117 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Accelerate Diagnostics
This chart shows the revenue of Accelerate Diagnostics, a company changing the fight against sepsis. Revenue is generated from sales of its system, which significantly accelerates bacterial identification and antibiotic susceptibility testing. This growth reflects the adoption of this technology in hospital laboratories to save lives.
Sales of companies in the market segment - Medanalysis
Accelerate Diagnostics is developing a platform for rapid bacterial identification and antibiotic susceptibility testing. Its revenue structure follows a "razor and blades" model: revenue comes from instrument sales and, more importantly, from the consumables required for each test.
Overall market sales
Accelerate Diagnostics, Inc. provides solutions for rapid infection diagnostics and antibiotic susceptibility testing. Demand for its technology depends on hospitals' efforts to combat sepsis and antibiotic resistance. This trend, reflecting the overall economic situation, influences healthcare budgets and hospitals' willingness to invest in advanced diagnostic platforms.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Accelerate Diagnostics
Accelerate Diagnostics provides solutions for rapid diagnosis of bloodstream infections, enabling faster antibiotic selection. This graph shows analysts' expectations for combating antibiotic resistance and the implementation of these systems in hospitals.
%20sales%20of%20the%20company%20Accelerate%20Diagnostics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Accelerate-Diagnostics&v=1772513438188 "Schedule of future (projected) sales of the company Accelerate Diagnostics")
Future (projected) sales of companies in the market segment - Medanalysis
Accelerate Diagnostics provides solutions for rapid microbial identification and antibiotic susceptibility testing. This chart presents a forecast for the medical analytics sector. It reflects the pressing global problem of antibiotic resistance and the need for rapid diagnostics to combat sepsis.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772513438199 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
The state of the healthcare system, reflected in this graph, directly impacts Accelerate Diagnostics. The company produces systems for rapid bacterial identification and antibiotic susceptibility testing. Demand for its products depends on hospital budgets and their commitment to combating antibiotic resistance.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513438220 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Accelerate Diagnostics
Accelerate Diagnostics provides solutions for rapid bacterial identification and antibiotic susceptibility testing. This graph shows the profitability of the fight against antimicrobial resistance. Profitability is driven by sales of its systems and cartridges to hospital laboratories.
Market segment marginality - Medanalysis
Accelerate Diagnostics develops and markets systems for rapid bacterial identification and antibiotic susceptibility testing, which is critical in sepsis treatment. Profitability depends on the implementation of its systems in hospital laboratories. This chart shows the average profitability in the sector, helping to assess the relevance of its technology in the fight against antibiotic resistance.
Market marginality as a whole
Accelerate Diagnostics provides a platform for rapid bacterial identification and antibiotic susceptibility testing. Demand for its products depends on hospitals' efforts to combat sepsis and antibiotic resistance. This dynamic, reflecting the state of the economy, impacts healthcare budgets, which determines hospitals' ability to invest in advanced diagnostic systems.
Employees in the company, segment and market as a whole
Number of employees in the company Accelerate Diagnostics
Accelerate Diagnostics provides solutions for rapid pathogen identification and antibiotic susceptibility testing. This chart shows the team that develops and markets these diagnostic systems. The progress demonstrates how the company strives to accelerate the adoption of its technologies in hospital laboratories to combat sepsis and antibiotic resistance.
Share of the company's employees Accelerate Diagnostics within the market segment - Medanalysis
Accelerate Diagnostics provides a platform for rapid pathogen identification and antibiotic susceptibility testing, which is critical in the fight against sepsis. This chart shows the company's share of the total number of specialists in the microbiological diagnostics sector, reflecting its innovative technology.
Number of employees in the market segment - Medanalysis
Accelerate Diagnostics, Inc. provides solutions for rapid microbial identification and antibiotic susceptibility testing. This chart, showing employment in the medical analytics sector, is important. The growth in the number of microbiologists and laboratory technicians reflects the global problem of antibiotic resistance and the urgent need for rapid diagnostics for appropriate treatment.
Number of employees in the market as a whole
Accelerate Diagnostics creates systems for rapid bacterial identification and antibiotic susceptibility testing. This overall occupancy chart reflects the financial health of hospitals. A stable economy provides funding that allows clinics to invest in technologies that save lives by reducing the time to an accurate diagnosis.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Accelerate Diagnostics (AXDX)
Accelerate Diagnostics (AXDX) is a company that produces systems for rapid sepsis diagnostics and antibiotic susceptibility testing. This represents "intellectual capital" in medical technology. Their value lies in their platform, which saves doctors time. This metric reflects the high valuation of their R&D and patents.
%20of%20the%20company%20Accelerate%20Diagnostics%20(AXDX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Accelerate-Diagnostics-AXDX&v=1772513438341 "Chart of market capitalization per employee (in thousands of dollars) of the company Accelerate Diagnostics (AXDX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
Accelerate Diagnostics creates tools for rapid bacterial identification and antibiotic susceptibility testing. This is a critical technology in the fight against superbugs. This figure demonstrates the high value the market can place on life-saving medical innovations, based on the development team.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772513438371 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Accelerate Diagnostics develops systems for rapid microbial identification and antibiotic susceptibility testing. This is a critical technology in the fight against sepsis. The high employee rating reflects the potential of its platform to save lives and save hospitals money, creating enormous value.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513438494 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Accelerate Diagnostics (AXDX)
Accelerate Diagnostics (AXDX) develops rapid diagnostic systems (such as Pheno) for identifying bacteria and determining their susceptibility to antibiotics. This is critical medical technology. This chart shows how much the company spends (negative profit) per employee (R&D, sales) trying to implement its expensive systems in hospital labs.
%20Chart%20Accelerate%20Diagnostics%20(AXDX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Accelerate-Diagnostics-AXDX&v=1772513438500 "Company Profit Per Employee (in thousands of dollars) Chart Accelerate Diagnostics (AXDX)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
Accelerate Diagnostics develops diagnostic platforms for rapid infection and antibiotic susceptibility testing. This chart shows how effectively the company sells its systems to hospitals. Success depends on demonstrating the clinical and economic value of its technologies, which accelerates patient treatment and reduces costs.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772513438505 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
Accelerate Diagnostics (AXDX) is a company that produces diagnostic systems (Pheno) for rapid antibiotic susceptibility testing. It is a MedTech diagnostics company. This indicator reflects the company's ongoing investment in its personnel (engineers and salespeople) to commercialize its sophisticated technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513438523 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Accelerate Diagnostics (AXDX)
Accelerate Diagnostics develops platforms for rapid diagnostics of infectious diseases. This chart shows how successfully the company is implementing its systems in hospital laboratories. The growth in revenue per employee demonstrates the importance of rapid diagnostics for saving lives.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Accelerate-Diagnostics-AXDX&v=1772513438530 "Sales chart per company employee Accelerate Diagnostics (AXDX)")
Sales per employee in the market segment - Medanalysis
Accelerate Diagnostics (AXDX) is a company whose platform (Pheno) promises to quickly identify bacteria and their antibiotic susceptibility, saving lives from sepsis. This chart shows their success. Their team's productivity lies in their ability to sell and install these expensive "devices" and "consumables" (cartridges) in hospitals.
Sales per employee for the market as a whole
Silvercorp Metals (SVM) is a mining company that extracts and produces metals, primarily silver, lead, and zinc, at its mines in China. It's a classic mining operation. This chart shows operational efficiency in mining. It reflects the revenue (dependent on metal prices) generated by each employee working at the mines and processing plants.
Short shares by company, segment and market as a whole
Shares shorted by company Accelerate Diagnostics (AXDX)
Accelerate Diagnostics (AXDX) is developing a system for rapid sepsis diagnostics. Despite the technology, hospital adoption is very slow. This chart shows the volume of short positions. The bears are betting that the company will burn through all its cash without achieving commercial success.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Accelerate-Diagnostics-AXDX&v=1772513438612 "Short Shares Chart for the Company Accelerate Diagnostics (AXDX)")
Shares shorted by market segment - Medanalysis
Accelerate Diagnostics (AXDX) develops systems for rapid bacterial identification and antibiotic susceptibility testing. The chart below shows a general short position on the medical diagnostics sector. It reflects investors' skepticism about the speed of hospital adoption of new tests.
Shares shorted by the overall market
Accelerate Diagnostics (AXDX) is a diagnostics company. When this fear indicator rises, investors fear that in a recession (1) patients will abandon "optional" tests and (2) routine testing volumes will decline. Investors are selling small, complex stories.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Accelerate Diagnostics (AXDX)
This oscillator is a barometer for the fight against sepsis for Accelerate Diagnostics. The company produces a system (Pheno) that quickly determines which antibiotic an infection is sensitive to. "Overheating" (above 70) occurs due to sales news. Slow hospital adoption and competition lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Accelerate-Diagnostics-AXDX&v=1772513438672 "RSI 14 indicator chart for the company's stock Accelerate Diagnostics (AXDX)")
RSI 14 Market Segment - Medanalysis
Accelerate Dx is an "ambulance" against *superbugs*. Their *platform* (Pheno) determines *bacterial sensitivity* to *antibiotics* (AST) in hours* (not days). The "Medanalysis" (diagnostics) sector thrives on R&D. RSI_14_Seg shows the "temperature" of the *entire* industry. It helps us understand: is AXDX's growth a niche or a general hype?
RSI 14 for the overall market
Accelerate Diagnostics (AXDX), a cash-burning biotech, is its lifeline. This chart is its lifeline. During periods of market euphoria, investors are willing to "buy the dream" and fund unprofitable R&D projects. In moments of panic, the money supply is turned off, and investors demand profits, not promises, which puts AXDX at risk of survival.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AXDX (Accelerate Diagnostics)
Accelerate Diagnostics (AXDX) is a company developing systems (Pheno) for rapid bacterial identification and antibiotic susceptibility testing (AST). This chart shows the analysts' average 12-month forecast, reflecting their view of how quickly hospitals will adopt this technology to combat sepsis.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AXDX-Accelerate-Diagnostics&v=1772513438753 "A chart showing analyst consensus forecasts for the expected stock price. AXDX (Accelerate Diagnostics)")
The difference between the consensus estimate and the actual stock price AXDX (Accelerate Diagnostics)
Accelerate Diagnostics (AXDX) is "fighting sepsis." Their platform (Pheno) promises to *quickly* (in hours, not days) determine which antibiotic will kill a blood infection. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe hospitals can implement this expensive but life-saving device.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AXDX-Accelerate-Diagnostics&v=1772513438769 "A chart showing the difference between the consensus forecast and the actual stock price. AXDX (Accelerate Diagnostics)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
Accelerate Diagnostics (AXDX) is a diagnostics company that developed a system (Pheno) that quickly determines which antibiotic a patient's bacteria is sensitive to. This chart shows general expectations for the medical testing sector. It reflects whether experts believe hospitals will demand rapid superbug tests.
Analysts' consensus forecast for the overall market share price
Accelerate Diagnostics (AXDX) is a company that "beats sepsis." Their Pheno platform identifies bacteria and its antibiotic resistance in hours (not days). This chart shows overall risk appetite. It reflects the degree to which investors believe conservative hospitals are willing to spend (CapEx) on implementing new, disruptive technologies.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Accelerate Diagnostics
Accelerate Diagnostics (AXDX) is accelerating the fight against sepsis. Their signature feature (Pheno) is an automated platform that quickly (in hours, not days) determines which antibiotics a patient's blood bacteria is sensitive to. This chart is a summary indicator of their razor and blade products. It reflects their (slow) ability to sell razors (equipment) to hospitals.
AKIMA Market Segment Index - Medanalysis
Accelerate Diagnostics is the fast lane in the world of testing. Their system dramatically reduces the time it takes to identify bacteria (causing sepsis) and select antibiotics, saving lives. This chart compares their composite index to the sector, showing how their rapid media analytics outperforms the competition.
The AKIM Index for the overall market
Accelerate Diagnostics is an in vitro diagnostics company offering rapid solutions for bacterial identification and antibiotic susceptibility testing. This chart, reflecting the market average, is a backdrop. It helps assess how AXDX, which is struggling for commercial adoption, compares to overall trends.
